New PD solutions and prescription options

INTRODUCTION

Characteristics of Icodextrin PD Solution (7.5%)

The MIDAS StudySummary of Study Results

Ultrafiltration with Icodextrin in CAPD

Ultrafiltration with Icodextrin in CAPD

Ultrafiltration Kinetics of Icodextrin Exchanges

Ultrafiltration with Icodextrin during PeritonitisCAPD

Ultrafiltration with Icodextrin during PeritonitisCCPD

Serum levels of icodextrin metabolites do not significantly increase during peritonitis

Conclusion

Study Description

UF Comparison for Glucose (Daytime Exchanges) and Icodextrin (Nightime Exchange) during 9 Peritonitis Episodes

Conclusion

Study Description

Total Cholesterol and LDL Cholesterol tend to lower in the icodextrin group.

In hypercholesterolemic patients receiving icodextrin, LDLc decreased by an average of 16%.

CONCLUSION

Skin Reactions (SR)

Serum Amylase 1

Serum Amylase 2

Icodextrin and Glucose tests

Icodextrin and Sodium levels

Metabolism of Icodextrin

Serum Levels of Icodextrin and Metabolites

Pharmacokinetics of Icodextrin

Extraneal™ May Extend CAPD Technique Survivalin Patients with UF Failure

Study Description

Mean Daytime UF Volume in Glucose and Icodextrin Patients during 12 months follow up.

Mean 24hr UF Volume in Glucose and Icodextrin Patients during 12 months follow up.

Mean dialysate creatinine clearance in APD patients using Icodextrin or Glucose solutions for the daytime dwell.

Summary of UF Results

Comparison of Icodextrin and Glucose Solutions for the Day time Dwell in ADP

Mean Daytime UF Volume in Glucose and Icodextrin Patients

Diapositiva PPT

After 1 month on Icodextrin, mean blood pressure was lower despite reduction of antihypertensive medication in 5 patients

CONCLUSION

Icodextrin PD Solution (7.5%)Summary

PHYSIONEAL FORMULATION

PHYSIONEAL FORMULATION

Product Description

FIRST CLINICAL STUDY

Bicarbonate Buffered PD Solution

Study Design

Diapositiva PPT

Pain Severity Rating ScalePeak Pain During Infusion

McGill Pain QuestionnaireTotal Weighted Pain Rating Index

PHASE III: DESIGN

PHASE III STUDY

Plasma Bicarbonate Values(Over whole year: data from the 57pts entering extension only)

PHASE III STUDY

Diapositiva PPT

Intraperitoneal pH vs. time

Addressing Malnutrition in PD

Protein-Energy Malnutrition

How Do We Identify Malnutrition?

Tools for Nutrition Assessment

Albumin as a Predictor

Albumin as a Negative Acute Phase Reactant

Diapositiva PPT

Diapositiva PPT

Malnutrition is Common in HD

Prevalence of Malnutrition is Similar in HD and PD*

Malnutrition in ESRDNutritional Needs in PD

Target Protein Intake for PD

How Can This Target Be Achieved?

Diapositiva PPT

Malnutrition in ESRDAims of Intraperitoneal AA

Nutrineal ® Characteristics

Relationship between Protein Intake and Phosphorus Intake

Diapositiva PPT

Nutrineal Absorption Study

Diapositiva PPT

Managing Protein Needs with Nutrineal

Diapositiva PPT

Nitrogen Balance Study

Diapositiva PPT

Evidence for a Positive Effect of Nutrineal on Protein Metabolism

Effects of an AA dialysate on leucine metabolism in CAPD patients

Study Description

Conclusion

Diapositiva PPT

Diapositiva PPT

Diapositiva PPT

Patient case 1: Hospital Dr.NegrinLas Palmas, Canaria Islands

Patient case 1: Hospital Dr.NegrinLas Palmas, Canaria Islands

Patient case 2 Hospital Dr.NegrinLas Palmas, Canaria Islands

Patient case 2: Hospital Dr.NegrinLas Palmas, Canaria Islands

Patient case 3: Hospital Dr.NegrinLas Palmas, Canaria Islands

Patient case 3 : Hospital Dr.NegrinLas Palmas, Canaria Islands